trans-RA16

trans-RA16 is an **in vitro-transcribed RNA aptamer** specifically developed to target and inhibit non-small cell lung cancer (NSCLC) cells, particularly the human NCI-H460 cell line[1][4][7]. It was discovered using in vivo SELEX (Systematic Evolution of Ligands by Exponential Enrichment). trans-RA16 binds to NCI-H460 cells with a dissociation constant (K_D) of approximately 12.14 nM, indicating strong affinity. It inhibits cell viability and tumor growth both in vitro and in vivo, with an IC_50 of approximately 105.7 nM. Its mechanism involves specific cell binding and likely internalization, leading to inhibition of tumor cell proliferation. In vivo imaging and RNA quantification studies demonstrated selective accumulation and retention of trans-RA16 in tumor tissues. syn-RA16 is a chemically synthesized version preferred for development but trans-RA16 remains a prototypic research agent for NSCLC aptamer therapy[1][4][7].